A citation-based method for searching scientific literature

Edmund Lee, William L Trepicchio, Judith L Oestreicher, Debra Pittman, Frank Wang, Francesca Chamian, Madhav Dhodapkar, James G Krueger. J Exp Med 2004
Times Cited: 660







List of shared articles



Times cited


Anti-drug antibodies of IL-23 inhibitors for psoriasis: a systematic review.
A Norden, J Y Moon, S S Javadi, L Munawar, J-T Maul, J J Wu. J Eur Acad Dermatol Venereol 2022
1

Novel Therapeutic Target(s) for Psoriatic Disease.
Vishal Thakur, Rahul Mahajan. Front Med (Lausanne) 2022
0

The Relapse of Psoriasis: Mechanisms and Mysteries.
Danning Tian, Yuping Lai. JID Innov 2022
0

Association Between Psoriasis and Nonalcoholic Fatty Liver Disease Among Outpatient US Adults.
Zhijie Ruan, Tao Lu, Yanxia Chen, Mengsi Yuan, Haoyang Yu, Ruimin Liu, Xiaoping Xie. JAMA Dermatol 2022
0

Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience.
Matteo Megna, Gabriella Fabbrocini, Eleonora Cinelli, Elisa Camela, Angelo Ruggiero. J Dermatolog Treat 2022
21


Psoriasis: Recent progress in molecular-targeted therapies.
Masaru Honma, Kei Hayashi. J Dermatol 2021
14

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis.
Jeremy G Light, Jennifer J Su, Steven R Feldman. Clin Cosmet Investig Dermatol 2021
0

Capsaicin attenuates imiquimod-induced epidermal hyperplasia and cutaneous inflammation in a murine model of psoriasis.
Tom C Chan, Meng-Sui Lee, Wen-Chih Huang, Wen-Yu Chang, James G Krueger, Tsen-Fang Tsai. Biomed Pharmacother 2021
1

Establishment of an Intradermal Ear Injection Model of IL-17A and IL-36γ as a Tool to Investigate the Psoriatic Cytokine Network.
David Kluwig, Sebastian Huth, Ali T Abdallah, Carolina M Pfaff, Katharina Fietkau, Laura Huth, Yvonne Marquardt, Jens M Baron, Bernhard Lüscher. Life (Basel) 2021
1

A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab.
Feras M Ghazawi, Farhan Mahmood, Leon Kircik, Yves Poulin, Marc Bourcier, Ronald Vender, Marni C Wiseman, Charles Lynde, Ivan V Litvinov. Front Med (Lausanne) 2021
4

Multifaceted Analysis of IL-23A- and/or EBI3-Including Cytokines Produced by Psoriatic Keratinocytes.
Kota Tachibana, Nina Tang, Hitoshi Urakami, Ai Kajita, Mina Kobashi, Hayato Nomura, Minori Sasakura, Satoru Sugihara, Fan Jiang, Nahoko Tomonobu,[...]. Int J Mol Sci 2021
1

Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities.
Alan Menter, Gerald G Krueger, So Yeon Paek, Dario Kivelevitch, Iannis E Adamopoulos, Richard G Langley. Dermatol Ther (Heidelb) 2021
7

Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis.
Kamran Ghoreschi, Anna Balato, Charlotta Enerbäck, Robert Sabat. Lancet 2021
53

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis.
Wendy Li, Rima Ghamrawi, Wasim Haidari, Steven R Feldman. Ann Pharmacother 2020
4

Current Developments in the Immunology of Psoriasis.
Franziska Grän, Andreas Kerstan, Edgar Serfling, Matthias Goebeler, Khalid Muhammad. Yale J Biol Med 2020
44

Interleukin-17A and Keratinocytes in Psoriasis.
Masutaka Furue, Kazuhisa Furue, Gaku Tsuji, Takeshi Nakahara. Int J Mol Sci 2020
60


Guselkumab in the treatment of moderate-to-severe plaque psoriasis.
Cristina López-Sánchez, Lluís Puig. Immunotherapy 2020
3

Tildrakizumab: A Review of Phase II and III Clinical Trials.
Sree S Kolli, Sarah D Gabros, Adrian Pona, Abigail Cline, Steven R Feldman. Ann Pharmacother 2019
13

Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.
A Al-Janabi, Z K Jabbar-Lopez, C E M Griffiths, Z Z N Yiu. Br J Dermatol 2019
6

Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study.
K Reich, P Rich, C Maari, R Bissonnette, C Leonardi, A Menter, A Igarashi, P Klekotka, D Patel, J Li,[...]. Br J Dermatol 2019
43